secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pluri Inc. (PLUR)
CIK:        0001158780
Form:       8-K
Filed at:   2025-04-17T23:59:59+00:00
Accession:  0001213900-25-032948
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Pluri's subsidiary loses $4.2M NIAID contract for PLX-R18 H-ARS therapy; termination for convenience effective April 15
--------------------------------------------------------------------------------

- Pluri Biotech Ltd. received termination notice from NIAID for a $4.2M contract awarded July 2023 to develop PLX-R18 for Hematopoietic Acute Radiation Syndrome.
- Termination effective April 15, 2025, for the government's convenience; Pluri links it to broader federal budgetary adjustments affecting NIH.
- Contract involved collaboration with AFRRI and USUHS; company is monitoring potential implications for other programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/0001213900-25-032948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1158780/000121390025032948/ea0238672-8k_pluri.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-032948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer